ArticleRadiation oncology (London, England)2016
Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic.
Article in Radiation oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Challenges in recurrent head and neck squamous cell cancer treatment: systematic review andClinical and translational radiation oncology · 2026Review
- Successful Treatment With Single-Fraction Stereotactic Body Radiotherapy to Lung and Reirradiation of Neck Node Metastases in a Treated Base Tongue Primary.Case reports in oncological medicine · 2025Article
- Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours.Journal of clinical medicine · 2024Review
- MR-guided stereotactic radiation therapy for head and neck cancers.Clinical and translational radiation oncology · 2024Article
- Patterns of failure for recurrent head and neck squamous cell carcinoma treated with salvage surgery and postoperative IMRT reirradiation.Clinical and translational radiation oncology · 2024Article
- Advancements of radiotherapy for recurrent head and neck cancer in modern era.Radiation oncology (London, England) · 2023Review
- Re-irradiation for head and neck cancer: outcome and toxicity analysis using a prospective single institution database.Frontiers in oncology · 2023Article
- Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.Cancers · 2022Review
- Re-irradiation for recurrent or second primary head and neck cancer.Radiation oncology journal · 2021Article
- Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects.Cancers · 2021Article
- Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy.Journal of neurological surgery. Part B, Skull base · 2020Article
- Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes.Head & neck · 2020Article
- Beyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies.Clinical and translational radiation oncology · 2020Article
- Overlapping volumes in re-irradiation for head and neck cancer - an important factor for patient selection.Radiation oncology (London, England) · 2020Article
- Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative.International journal of radiation oncology, biology, physics · 2018Article
- Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis.International journal of radiation oncology, biology, physics · 2018Article
- Reirradiation of Skull Base Tumors With Advanced Highly Conformal Techniques.Current oncology reports · 2017Review
- Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes.Oncotarget · 2017Article
- Article
- Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.Cancer medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe reviewed outcomes of patients with loco-regionally recurrent (LRR) or new primary (NP) squamous cell carcinoma of the head and neck (SCCHN) treated at our institution with reirradiation (RRT).
methodsPatients received definitive RRT (DRRT) or post-operative RRT following salvage surgery (PRRT) from 2003 to 2011. Measured survival outcomes included loco-regional relapse free survival (LRFS) and overall survival (OS).
resultsAmong 81 patients (PRRT, 42; DRRT, 39), median PRRT and DRRT doses were 60 Gy (12-70 Gy) and 69.6 Gy (48-76.8 Gy). The majority of patients received IMRT-based RRT (n = 77, 95 %). With median follow-up of 78.1 months (95 % CI, 56-96.8 months), 2-year OS was 53 % with PRRT and 48 % with DRRT (p = 0.12); 23 % of patients were alive at last follow-up. LRFS at 2 years was 60 %, and did not differ significantly between PRRT and DRRT groups. A trend toward inferior LRFS was noted among patients receiving chemotherapy with RRT versus RRT alone (p = 0.06). Late serious toxicities were uncommon, including osteoradionecrosis (2 patients) and carotid artery bleeding (1 patient, non-fatal).
conclusionsOS of PRRT- and DRRT-treated patients in this series appears superior to the published literature. We used IMRT for the majority of patients, in contrast to several series and trials previously reported, which may account in part for this difference. Future studies should seek to improve outcomes among patients with LRR/NP SCCHN via alternative therapeutic modalities such as proton radiotherapy and by incorporating novel systemic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.